



---

# Autodisplay Biotech - New Approach for Biocatalysis, Drug Discovery and Bioanalytics

## Company Overview and Investment Opportunity

---

Investorenkonferenz CIB Frankfurt  
„Investieren in Weiße Biotechnologie“

Frankfurt, May 31, 2010

**Autodisplay  
Biotech**

## Copyright and Disclaimer

### Copyright

- All rights for the use of all or parts of the information in this document, including reprinting the whole document or parts thereof, the storage in databanks and translations remain with Autodisplay Biotech
- Individual charts can be reproduced stating Autodisplay Biotech as source; please contact Autodisplay Biotech, should you wish to reproduce larger parts of this document

### Disclaimer


- Autodisplay Biotech has prepared this document to the best of Autodisplay Biotech's knowledge and belief based on all available information
- Autodisplay Biotech takes no warranty for the accuracy and completeness of this information
- Before deducting individual conclusions, it is necessary to obtain additional data and conduct further analyses
- Therefore, all liability for costs or damage resulting from information and conclusions in this document is excluded

**Autodisplay Biotech is developing a technology platform for biocatalysis, drug discovery and bioanalytics applications**

<b>Business areas/models</b>	<b>Milestones</b>
<ul style="list-style-type: none"><li>• <b>Business areas</b><ul style="list-style-type: none"><li>- Biocatalysis (development and production)</li><li>- Drug discovery (small molecule and small protein drugs)</li><li>- Bioanalytics (biochips, ELISA)</li></ul></li><li>• <b>Business models</b><ul style="list-style-type: none"><li>- Service provider</li><li>- Out-licensing of own intellectual property (IP)</li><li>- Production of selected biocatalysts and bioanalytics tools</li></ul></li></ul>	<ul style="list-style-type: none"><li>• Founded in May 2008 as spin-off of the University of Dusseldorf</li><li>• Technological proof-of-concept in the areas of biocatalysis, drug discovery and bioanalytics</li><li>• Access through licensing contract to all major basic patents granted (Max-Planck-Society, Saarland University)</li><li>• First own patent applications</li><li>• Established member of the biotech community (e.g. CIB Frankfurt and CLIB 2021)</li></ul>


**Autodisplay technology enables the display of proteins on the surface of *Escherichia coli* (*E. coli*)**

### Advantages




- Proteins on the surface
  - Immobilised and stabilised
  - Fully accessible
  - Dimerisation / aggregation of multi protein complexes possible
- Very easy purification
- DNA as internal label
- Self replication
- Analytics by optical methods (e.g. fluorescence activated cell sorting)


As each *E. coli* has a different protein on its surface, the screening of chemical reactions or the binding of external proteins is possible



## Biocatalysis: Development of new biocatalysts and cost-effective production of biocatalysts




A new, cost efficient biocatalytic concept can be realised with autodisplay biocatalysts



Source: Expert and client discussions


## Biocatalysis - Cost Savings

In the case that an immobilisation of the biocatalyst is not necessary, 65% of the costs can be saved using the autodisplay biocatalysts




Source: Expert and client discussions 1) Production of a standard pharma biocatalyst in a 30qm fermenter

**With the immobilisation of the biocatalysts, 80% of the costs could be saved using autodisplay biocatalysts**



Source: Expert and client discussions 1) Production of a standard pharma biocatalyst in a 30qm fermenter

## Drug discovery: Discovery of new small molecule drugs and small protein drugs



**Bioanalytics: Development of new bioanalytical tools (biochips, ELISA) and cost-effective production of bioanalytical tools**

